The human endometrium has a remarkable capacity for scar-free repair after the inflammatory process of menstruation ([@B1], [@B2]). Currently, our understanding of this process is limited, with the factors involved and their regulation remaining elusive. Delayed repair may result in the common gynecological complaint of prolonged, heavy menstrual bleeding (HMB). One in three women considers their menstruation excessive, rising to one in two as menopause approaches ([@B3]). Although medical treatment options are available, a significant proportion of women require surgery due to treatment failure ([@B4]). It is essential to fully understand the endometrial repair processes to improve medical treatments and avoid surgical risks. Furthermore, elucidating the mechanisms of efficient endometrial repair may have wider implications, identifying novel treatment targets in tissue sites where persistent inflammation and scarring are problematic.

Angiogenesis is mandatory for efficient repair and remodeling. Vascular endothelial growth factor (VEGF) is a key factor in physiological and pathological angiogenesis ([@B5]--[@B7]). This secreted protein stimulates endothelial cell proliferation and migration ([@B5], [@B8], [@B9]). It acts through two receptors, VEGFR1 and VEGFR2, both expressed in the human endometrium ([@B10], [@B11]). In the primate, VEGF is essential for neoangiogenesis during postmenstrual repair ([@B9]). Aberrant endometrial expression of VEGF has been demonstrated in women with HMB, with lower levels in these women compared with normal controls ([@B12]). However, the regulation of VEGF during endometrial repair remains undefined.

As the corpus luteum regresses at the end of the menstrual cycle, progesterone levels fall. This triggers the release of inflammatory mediators within the endometrium that initiate menstruation ([@B1]). Although endometrial repair was traditionally considered to be regulated by estrogen, research in the mouse model of simulated menstruation has suggested it may be an estrogen-independent event ([@B13]). We propose that progesterone withdrawal simultaneously initiates menstruation and repair. After progesterone withdrawal, there is an increase in endometrial prostaglandin (PG) synthesis, namely PGE~2~ and PGF~2α~ ([@B1], [@B14]). PGF~2α~ is a potent vasoconstrictor and, alongside other factors, acts on the spiral arterioles to cause intense vasoconstriction premenstrually ([@B15]). The role of PGE~2~ during endometrial repair has not been fully defined. Spiral arteriole vasoconstriction is likely to cause an episode of transient, local hypoxia in the uppermost endometrial zones. Classic experiments in the rhesus monkey first suggested the presence of perimenstrual hypoxia ([@B15]). More recently, use of a marker of cell hypoxia, pimonidazole, in mice has confirmed oxygen levels below 10 mm Hg during menstruation ([@B9]). Hypoxia-inducible factor 1 (HIF-1) is a transcription factor known to regulate the cellular response to hypoxia. In hypoxic conditions the two subunits (HIF-1α and HIF-1β) dimerize and initiate transcription of target genes, including factors involved in angiogenesis ([@B16]--[@B18]). HIF has been identified in the human endometrium during the late secretory and menstrual phases ([@B19]).

We hypothesized that 1) VEGF is increased during menstruation when endometrial repair is initiated, and 2) this increase is regulated by progesterone withdrawal, PG synthesis, and hypoxic conditions. Herein we demonstrate endometrial VEGF expression is maximal during the menstrual phase. In vitro endometrial cell studies revealed that hypoxia, PGE~2~, and PGF~2α~ induce VEGF expression. Ex vivo endometrial explant studies showed that VEGF expression was increased by hypoxia and PG only in tissue from the secretory phase. However, when proliferative explants were exposed to progesterone in vitro followed by progesterone withdrawal in hypoxic conditions, VEGF expression was significantly increased. Furthermore, we show that hypoxia regulates VEGF expression via HIF-1α, whereas PGF~2α~ induces VEGF expression independently of HIF-1α.

Materials and Methods
=====================

Human endometrial tissue collection
-----------------------------------

Endometrial biopsies (n = 47) were collected with a suction curette (Pipelle, Laboratorie CCD, Paris, France) from women (median age 42 yr, range 22--50) attending the gynecological outpatient department. All reported regular menstrual cycles (21--35 d) and no exogenous hormone exposure for 3 months before biopsy. Women with large fibroids (\>3 cm) or endometriosis were excluded. Tissue was divided and 1) placed in RNAlater, RNA stabilization solution \[Ambion (Europe) Ltd., Warrington, UK\], 2) fixed in neutral buffered formalin for wax embedding, and 3) placed in PBS for in vitro culture. Biopsies were consistent for 1) histological dating \[criteria of Noyes *et al.* ([@B20])\], 2) reported last menstrual period, and 3) serum progesterone and estradiol concentrations at time of biopsy ([Table 1](#T1){ref-type="table"}). Seven women providing a biopsy in the proliferative, early/mid-secretory phase returned for an additional biopsy 3--6 months after insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) for management of heavy menstrual bleeding. Written consent was obtained from participants and ethical approval granted from the Lothian Research Ethics Committee.

###### 

Serum estradiol and progesterone levels at the time of endometrial biopsy

                    Number   Mean estradiol levels \[pmol/liter (range)\]   Mean progesterone levels \[nmol/liter (range)\]
  ----------------- -------- ---------------------------------------------- --------------------------------------------------------
  Menstrual         8        197.25 (55--514)                               3.71 (1.24--10.59)[*^a^*](#TF1-1){ref-type="table-fn"}
  Proliferative     14       476.18 (79--1105)                              2.68 (0.97--7.1)[*^a^*](#TF1-1){ref-type="table-fn"}
  Early secretory   9        497.50 (289--841)                              59.60 (23.2--112.91)
  Mid secretory     10       638.00 (242--1949)                             64.30 (25.47--114.53)
  Late secretory    6        318.22 (59.09--819)                            8.22 (1.06--16.95)[*^a^*](#TF1-1){ref-type="table-fn"}

Progesterone levels are significantly lower than in the early-mid secretory phases (*P* \< 0.001).

Immunohistochemistry
--------------------

The 3-μm paraffin sections were dewaxed and rehydrated. Antigen retrieval was undertaken by microwaving sections in a high-pH heat-induced antigen retrieval buffer (pH 9.0). Endogenous peroxidase activity was blocked by 3% hydrogen peroxide. Sections were sequentially incubated in avidin and biotin (Vector Laboratories, Peterborough, UK) and protein block (Dako, Cambridge, UK). Mouse monoclonal anti-VEGF antibody (12.4 μg/ml; R&D Systems, Abingdon, UK) was applied overnight at 4 C. Negative controls were incubated with an equivalent concentration of mouse IgG2B. Biotinylated rabbit antimouse secondary antibody was used at 1:200. Avidin-biotin-peroxidase complex (ABC-Elite; Vector) was applied for 30 min and liquid diaminobenzidine kit (Zymed Laboratories, San Francisco, CA) used for detection. The reaction was stopped with distilled water and sections counterstained with hematoxylin, dehydrated, and mounted with Pertex (Cellpath plc, Hemel Hempstead, UK).

Culture of endometrial explants
-------------------------------

All explants were cultured on sterile capillary bedding just covered with serum-free RPMI 1640 medium to minimize tissue hypoxia. Four experiments were carried out.

1\) Proliferative (n = 3) and secretory (n = 3--6) phase biopsies were divided into four equal explants and treated with vehicle or 100 n[m]{.smallcaps} PGF~2α~ and placed in normoxic conditions (21% O~2~, 5% CO~2~, 37 C) or in a sealed hypoxic chamber (0.5% O~2~, 5% CO~2~, 37 C; Coy Laboratory Products, Grass Lake, MI) for 24 h.

2\) Proliferative biopsies (n = 4) were divided into eight explants. All were treated with 1 μ[m]{.smallcaps} medroxyprogesterone acetate (MPA) for 24 h. Explants were then treated for 48 h with 1) 1 μ[m]{.smallcaps} MPA plus vehicle, 2) 1 μ[m]{.smallcaps} MPA plus 8.4 μ[m]{.smallcaps} indomethacin \[a cyclooxygenase (COX) inhibitor\], 3) 1 μ[m]{.smallcaps} MPA plus 1 μ[m]{.smallcaps} mifepristone (RU486, a progesterone receptor antagonist), or 4) 1 μ[m]{.smallcaps} MPA plus 1 μ[m]{.smallcaps} mifepristone plus 8.4 μ[m]{.smallcaps} indomethacin. This 48-h incubation was carried out in both normoxic and hypoxic conditions.

3\) Four additional endometrial biopsies were divided into four explants and treated with progesterone (1 μ[m]{.smallcaps}) for 24 h before washing with PBS followed by treatment with progesterone or vehicle in normoxic and hypoxic conditions for 48 h.

4\) Endometrial tissue from across the menstrual cycle (n = 22) was weighed and cultured for 24 h in 1 ml RPMI 1640 at 37 C in normoxia and the culture supernatant analyzed by ELISA.

Culture of endometrial cells
----------------------------

Human Ishikawa endometrial adenocarcinoma cells (European Collection of Cell Cultures, Centre for Applied Microbiology, Wiltshire, UK) were stably transfected with the PGF~2α~ receptor (FPS cells) ([@B21]). Primary human endometrial stromal (HES) cells were isolated from endometrial tissue (n = 3) by enzymatic digestion as previously described ([@B22]).

To determine the effect of PGF~2α~ and/or hypoxic conditions on VEGF expression, approximately 4 × 10^5^ FPS or HES cells were seeded in six-well plates. The following day, cells were incubated in serum-free culture medium containing 8.4 μ[m]{.smallcaps} indomethacin (COX enzyme inhibitor) for at least 16 h. Cells were then treated with vehicle or 100 n[m]{.smallcaps} PGF~2α~ and placed in normoxia (21% O~2~, 5% CO~2~, 37 C) or a sealed hypoxic chamber (0.5% O~2~, 5% CO~2~, 37 C) for 2, 4, 8, 24, and 48 h.

Two different 19-nucleotide short hairpin RNA (shRNA) sequences derived from human HIF-1α mRNA (U22431; bp 1470--1489 and bp 2192--2211) and a scrambled control oligonucleotide were used and have been described previously ([@B23], [@B24]). These sequences are termed HIF-1α/shRNA1470 and HIF-1α/shRNA2192. Cells were transiently transfected with the shRNA sequences using a lentiviral vector at MOI 10 for 24 h. Cells were incubated in serum-free medium overnight before placement in the hypoxic chamber for 8 h. Cells were washed with PBS and harvested, and RNA or protein was extracted for PCR or Western blot analysis.

Quantitative RT-PCR
-------------------

Expression of VEGF in endometrial tissue and cells was determined by quantitative RT-PCR (TaqMan) analysis. Total RNA from cells and endometrial biopsies was extracted using the RNeasy Mini Kit (QIAGEN Ltd., Sussex, UK) according to manufacturer\'s instructions. Samples were treated for DNA contamination by DNA digestion during RNA purification. RNA samples were reverse transcribed using MgCl~2~ (5.5 m[m]{.smallcaps}), deoxy (d) nucleotide triphosphates (0.5 m[m]{.smallcaps} each) random hexamers (2.5 μ[m]{.smallcaps}), ribonuclease inhibitor (0.4 U/μl), and multiscribe reverse transcriptase (1.25 U/μl; all from PE Biosystems, Warrington, UK); 200--400 ng of RNA was added. A tube with no reverse transcriptase and another tube with water were included as controls. To measure cDNA expression, a reaction mix was prepared containing TaqMan buffer (5.5 m[m]{.smallcaps} MgCl~2~, 200 μ[m]{.smallcaps} dATP 200 μ[m]{.smallcaps} dCTP, 200 μ[m]{.smallcaps} dGTP, 400 μ[m]{.smallcaps} deoxyuridine triphosphate), ribosomal 18S primers/probe (Applied Biosystems, Warrington, UK) and specific forward and reverse primers and probes: VEGF forward primer 5′-TACCTCCACCATGCCAAGT-3′, reverse primer 5′-TAGCTGCGCTGATAGACAT-3′, and probe 5′-ACTTCGTGATGATTCTGCC-3′; lamin A/C forward primer 5′-AGCAAAGTGCGTGAGGAGTT-3′, reverse primer 5′-AGGTCACCCTCCTTCTTGGT-3′, and Universal probe library no. 17. A 0.4-μl volume of cDNA was added for each PCR. Negative controls (water instead of cDNA) were included in each run. PCR was carried out using ABI Prism 7900 (Applied Biosystems). Samples were analyzed in triplicate using Sequence Detector version 2.3 (PE Biosystems). Expression of target mRNA was normalized to RNA loading for each sample using the 18S rRNA as an internal standard. There was no significant change in 18S rRNA expression between normoxic and hypoxic conditions.

Nuclear protein extraction
--------------------------

Cytoplasmic proteins were extracted from endometrial epithelial (FPS) cells with a cytoplasmic protein lysis buffer \[10 m[m]{.smallcaps} HEPES (pH 7.8), 10 n[m]{.smallcaps} KCl, 2 m[m]{.smallcaps} MgCl~2~, 1 m[m]{.smallcaps} dithiothreitol, 0.1 m[m]{.smallcaps} EDTA, 10% Nonidet P-40\] containing protease inhibitors (Roche Diagnostics Ltd., Lewes, UK). The membrane fraction was pelleted by centrifugation at 13,000 rpm for 1 min at 4 C. Cytoplasmic fraction supernatant was removed and stored at −80 C. The nuclear fraction was extracted with a nuclear protein lysis buffer \[50 m[m]{.smallcaps} HEPES (pH 7.8), 50 n[m]{.smallcaps} KCl, 300 m[m]{.smallcaps} NaCl, 0.1 m[m]{.smallcaps} EDTA, 1 m[m]{.smallcaps} dithiothreitol, 10% glycerol\] containing protease inhibitors (Roche) followed by agitation for 20 min at 4 C and centrifugation at 13,000 rpm for 5 min at 4 C. Nuclear fraction supernatant was stored at −80 C. Protein content was determined using protein assay kits (Bio-Rad, Hemel Hempstead, UK).

HIF-1α Western blot analysis
----------------------------

A total of 15 μg nuclear protein from FPS cells was resuspended in a 2:1 ratio with Laemmli buffer \[125 m[m]{.smallcaps} Tris-HCl (pH 6.8), 4% sodium dodecyl sulfate, 5% 2-mercaptoethanol, 20% glycerol, and 0.05% bromophenol blue\] and denatured for 5 min at 90 C. Proteins were separated on 4--12% Bis-Tris gels (NuPAGE Novex; Invitrogen, Carlsbad, CA) and transferred onto polyvinylidene difluoride membranes (Millipore, Watford, UK). Membranes were blocked overnight before incubation with primary antibodies for 2 h at room temperature: mouse monoclonal HIF-1α antibody (BD Biosciences, Oxford, UK) at 1:250 and rabbit polyclonal to β-actin (Abcam, Cambridge, UK) at 1:5000. After washing, the membrane was incubated with horseradish peroxidase-conjugated goat antimouse IgG (Dako) or horseradish peroxidase-conjugated mouse antirabbit IgG (Sigma Aldrich Company Ltd. Dorset, UK) at 1:20000. Chemiluminescent horseradish peroxidase substrate (Immobilon Western; Millipore Corp., Billerica, MA) was used for detection according to manufacturer\'s instructions.

VEGF ELISA
----------

Levels of VEGF in culture supernatants were determined in triplicate samples using a commercially available ELISA kit (PeproTech, London, UK), according to manufacturer\'s instructions. Protein values in explant experiments were normalized for tissue weight.

Statistics
----------

For cell and tissue culture, mRNA results are expressed as fold increase, where relative expression of mRNA on treatment was divided by the relative expression after vehicle treatment. Data are presented as mean ± [sem]{.smallcaps}, and significance of raw data was determined using one-way ANOVA with Tukey\'s multiple-comparison test. For endometrium from across the menstrual cycle, mRNA results are expressed as quantity relative to a comparator, a sample of RNA from the liver. Significant differences in mRNA and protein were determined using Kruskal-Wallis nonparametric test with Dunn\'s multiple-comparison posttest (Prism version 4.02; GraphPad Software, Inc., San Diego, CA).

Results
=======

VEGF levels are increased at menstruation
-----------------------------------------

Endometrial VEGF mRNA expression varied significantly across the menstrual cycle (*P* = 0.0005) ([Fig. 1](#F1){ref-type="fig"}A). Maximal expression was observed in menstrual endometrium, when levels were significantly higher than in the proliferative (*P* \< 0.05) and early secretory (*P* \< 0.01) phases. VEGF protein secreted by endometrial explants from across the menstrual cycle was measured by ELISA. VEGF protein secretion was significantly greater from proliferative explants compared with late secretory endometrium (*P* \< 0.05) ([Fig. 1](#F1){ref-type="fig"}B). Immunolocalization of VEGF protein in menstrual endometrium ([Fig. 1](#F1){ref-type="fig"}C) showed positive cytoplasmic staining in the surface epithelial cells (SE), glandular epithelial cells (GE), stromal compartment (St), and perivascular cells (*arrows*).

![Endometrial VEGF is increased during menstruation. A, VEGF mRNA expression in endometrial biopsies from across the menstrual cycle; B, VEGF secreted protein from endometrial explants collected at each menstrual cycle stage; C, immunolocalization of VEGF in menstrual endometrium; D, menstrual negative control tissue. ES, Early-secretory; GE, glandular epithelial cells; KW, Kruskal Wallis; LS, late-secretory; M, menstrual; MS, mid-secretory; P, proliferative; SE, surface epithelial cells; St, stromal cell compartment. \*, *P* \< 0.05; \*\*\*, *P* \< 0.001. *Arrows* indicate perivascular cells. *Scale bar*, 50 μm.](zeg0081182350001){#F1}

Regulation of VEGF in endometrial epithelial cells
--------------------------------------------------

An endometrial epithelial cell line stably transfected with the PGF~2α~ receptor (FPS cells) was used to investigate the regulation of VEGF expression. This cell line was used because primary endometrial epithelial cells have a limited capacity for proliferation in culture but do contain this PG receptor *in vivo* ([@B25], [@B26]). FPS cells treated with 100 n[m]{.smallcaps} PGF~2α~ or hypoxia showed a trend toward increased VEGF mRNA expression; this increase reached significance when both factors were present simultaneously (*P* \< 0.05) ([Fig. 2](#F2){ref-type="fig"}A). VEGF secreted protein levels were significantly increased in the culture supernatants from FPS cells treated for 24 h with PGF~2α~, hypoxia, or both (*P* \< 0.001) ([Fig. 2](#F2){ref-type="fig"}B).

![The regulation of VEGF in human endometrial cells. A, VEGF mRNA expression in a human endometrial epithelial cell line (FPS cells) treated with vehicle, 100 n[m]{.smallcaps} PGF~2α~, hypoxia, or both hypoxia and PGF~2α~ for 24 h; B, VEGF secreted protein levels in the culture supernatants from FPS cells; C, VEGF mRNA expression in primary HES cells treated with vehicle, 100 n[m]{.smallcaps} PGF~2α~, hypoxia, or both hypoxia and PGF~2α~ for 24 h; D, VEGF secreted protein levels in the culture supernatants from these HES cells. All results are from three separate experiments; HES cells were isolated from three different women. Normoxia = 21% O~2~; hypoxia = 0.5% O~2~. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](zeg0081182350002){#F2}

Regulation of VEGF in primary HES cells
---------------------------------------

Treatment of HES cells with 100 n[m]{.smallcaps} PGF~2α~ in normoxia had no effect on VEGF mRNA expression ([Fig. 2](#F2){ref-type="fig"}C). However, incubation of HES cells in hypoxic conditions for 24 h revealed a significant increase in VEGF (*P* \< 0.01). Simultaneous treatment of HES cells with PGF~2~ and hypoxia also significantly elevated VEGF mRNA expression (*P* \< 0.01) ([Fig. 2](#F2){ref-type="fig"}C). VEGF secreted protein levels were significantly increased when HES cells were incubated for 24 h with PGF~2α~ and hypoxia *vs.* vehicle-treated cells in normoxia (*P* \< 0.05) ([Fig. 2](#F2){ref-type="fig"}D).

Regulation of VEGF levels in human endometrial tissue explants
--------------------------------------------------------------

Proliferative endometrial explants treated with 100 n[m]{.smallcaps} PGF~2α~ in normoxia or hypoxia showed no significant changes in VEGF mRNA expression ([Fig. 3](#F3){ref-type="fig"}A). In contrast, explants from the secretory phase displayed significant increases in VEGF mRNA expression after cotreatment with PGF~2α~ and hypoxia (*P* \< 0.05) ([Fig. 3](#F3){ref-type="fig"}B). This varied response between endometrium from the proliferative and secretory phase suggests previous progesterone exposure may influence the ability of tissue to respond.

![The effect of progesterone withdrawal, prostaglandins, and hypoxia on VEGF expression in the endometrium. A, VEGF mRNA expression in endometrial explants from the proliferative phase treated with vehicle, 100 n[m]{.smallcaps} PGF~2α~, hypoxia, or both hypoxia and PGF~2α~ (n = 3) for 24 h. B, VEGF mRNA expression in secretory endometrial explants treated with vehicle, 100 n[m]{.smallcaps} PGF~2α~, hypoxia, or both hypoxia and PGF~2α~ (n = 3) for 24 h. C, Proliferative-phase explants (n = 4) were pretreated with1 μ[m]{.smallcaps} MPA and then 1) maintained in 1 μ[m]{.smallcaps} MPA (P), 2) cotreated with 1 μ[m]{.smallcaps} MPA and 1 μ[m]{.smallcaps} RU486, a progesterone receptor antagonist (P+RU486), or 3) cotreated with 1 μ[m]{.smallcaps} MPA, 1 μ[m]{.smallcaps} RU486, and 8.4 μ[m]{.smallcaps} indomethacin, a COX enzyme inhibitor (P+RU486+IndoM). Identical treatments were incubated in either normoxia (21% O~2~) or hypoxia (0.5% O~2~). D, Endometrial explants pretreated with 1 μ[m]{.smallcaps} progesterone followed by maintenance in progesterone (P) or incubation with vehicle to induce progesterone withdrawal (Pw/d) in normoxia and hypoxia. E, Insertion of the LNG-IUS (IUS), with consequent local reduction in progesterone receptor expression analogous to local progesterone withdrawal, resulted in a significant increase in VEGF mRNA expression; note logarithmic scale on y-axis. Normoxia = 21% O~2~; hypoxia = 0.5% O~2~. \*, *P* \< 0.05; \*\*, *P* \< 0.01.](zeg0081182350003){#F3}

The effect of progesterone, and its withdrawal, on VEGF expression
------------------------------------------------------------------

To test the hypothesis that previous progesterone exposure is necessary for VEGF induction, we used ex vivo models of progesterone withdrawal. Proliferative endometrial biopsies were divided into eight equal explants and pretreated for 24 h with progestin (MPA). Explants were then cotreated with MPA plus 1) vehicle; 2) indomethacin, a COX inhibitor; 3) a progesterone receptor antagonist (RU486); or 4) RU486 and indomethacin for 48 h. Ex vivo progesterone antagonism in normoxia did not show significant up-regulation of VEGF mRNA ([Fig. 3](#F3){ref-type="fig"}C). *in vivo*, progesterone withdrawal is followed by hypoxia due to spiral arteriole vasoconstriction. When we antagonized progesterone in hypoxic conditions to mimic the *in vivo* scenario more accurately, there was a significant increase in VEGF mRNA expression ([Fig. 3](#F3){ref-type="fig"}C). This increase was abrogated by cotreatment with indomethacin to suppress PG production, suggesting that both hypoxia and PG are necessary to increase endometrial VEGF expression after progesterone withdrawal. Because synthetic agents such as MPA and RU486 may have off-target effects, additional endometrial biopsies were treated with progesterone for 24 h before treatment with vehicle or maintenance in progesterone. Again, only explants exposed to progesterone withdrawal in hypoxic conditions showed a significant increase in VEGF expression (*P* \< 0.05) ([Fig. 3](#F3){ref-type="fig"}D).

We examined paired endometrial biopsies collected from the same woman before and 3--6 months after LNG-IUS insertion (n = 7). The LNG-IUS is known to down-regulate the endometrial progesterone receptor ([@B27]) and may represent an *in vivo* model of progesterone deprivation. We identified a significant up-regulation of VEGF mRNA expression in endometrium collected after LNG-IUS insertion when compared with preinsertion biopsies (*P* \< 0.05) ([Fig. 3](#F3){ref-type="fig"}D).

The contribution of HIF-1α to the regulation of endometrial VEGF
----------------------------------------------------------------

To assess the contribution of the transcription factor HIF-1α to endometrial VEGF expression, we transfected FPS cells with two different shRNA sequences against HIF-1α (HIF-1α/sh1470 and HIF-1α/sh2192) and confirmed HIF-1α silencing by Western blot analysis ([Fig. 4](#F4){ref-type="fig"}A). Transfection with either sequence reduced HIF-1α protein levels in response to hypoxia, whereas a control scrambled sequence had no such effect ([Fig. 4](#F4){ref-type="fig"}A). Specificity of the shRNA sequences was examined by measurement of lamin A/C mRNA levels, which revealed no significant changes upon transfection with any construct ([Fig. 4](#F4){ref-type="fig"}B). HIF-1α silencing had no significant impact on PGF~2α~-induced VEGF mRNA expression ([Fig. 4](#F4){ref-type="fig"}C). In contrast, hypoxic induction of VEGF was significantly lower in cells where HIF-1α was silenced when compared with untransfected cells or cells transfected with HIF-1α/shSCR (*P* \< 0.05) ([Fig. 4](#F4){ref-type="fig"}D).

![HIF-1α silencing in FPS cells prevents hypoxic induction of VEGF- but not PGF2α-mediated increases. A, Confirmation of HIF-1α protein knockdown by Western blot with transfection of two short hairpin sequences against HIF-1α (HIF-1/sh1470 and HIF-1α/sh2192), compared with a scrambled sequence (shSCR) or untransfected cells after 8 h in hypoxic conditions (0.5% O~2~); B, specificity of the knockdown was confirmed by examining lamin A/C mRNA expression, which showed no significant changes with transfection of any construct; C, silencing of HIF-1α had no significant effect on PGF~2α~-mediated VEGF expression; D, cells transfected with shRNA against HIF-1α had a significantly abrogated response to hypoxic stimulation, with low levels of VEGF expression compared with untransfected cells or those transfected with a scrambled sequence. \*, *P* \< 0.05; \*\*, *P* \< 0.01; ns, nonsignificant.](zeg0081182350004){#F4}

Discussion
==========

The novel data presented herein detail the requirement for progesterone withdrawal, hypoxic conditions, and PG production to increase endometrial VEGF during menstruation. We confirm that hypoxia increases endometrial VEGF production and describe, for the first time, its dependence upon endometrial HIF-1α. In addition, we reveal a novel PGF~2α~-mediated increase in endometrial VEGF expression that is independent of HIF-1α.

Electron microscopy of the human endometrium has shown that repair commences on d 2 of the menstrual cycle ([@B28]). Because repair is initiated at menstruation, the factors involved must be up-regulated during this phase. Herein we have shown significant up-regulation of endometrial VEGF mRNA and protein during menstruation. This is consistent with findings in the rhesus macaque, where heightened expression of VEGF was present in the newly formed surface epithelium and stroma during postmenstrual repair ([@B29]). Previous immunohistochemical and *in situ* hybridization studies have also shown increased VEGF expression in the human endometrium during menstruation ([@B30], [@B31]). VEGF is a potent angiogenic factor that stimulates endothelial cell proliferation and migration ([@B5]). A recent study examining the decidualized mouse uterus and rhesus macaque endometrium found that VEGF blockade with VEGF-Trap (a VEGF blocker) completely inhibited neovascularization and reepithelialization during endometrial repair ([@B9]). Interestingly, a previous study of the human endometrium found significantly decreased VEGF mRNA and protein levels in women with HMB when compared with controls ([@B12]). Therefore, delineation of the regulation of this important repair factor may provide novel therapeutic targets for HMB.

Herein we have shown that progesterone withdrawal, hypoxia, and PG production are required to increase VEGF expression in endometrial explants. An elegant study of ovariectomized, artificially cycling macaques reported an estrogen-independent elevation in stromal VEGF immediately after progesterone withdrawal ([@B29]). An estrogen-dependent increase in VEGF occurred subsequently, during the proliferative phase, suggesting estradiol is involved in remodeling but not in the initial phase of endometrial repair. Our ex vivo models further delineate events after progesterone withdrawal in the human endometrium. Progesterone withdrawal appears necessary, but alone is not sufficient, to induce endometrial VEGF. Downstream hypoxia and PG production are also required for endometrial VEGF expression. Previous studies have shown hypoxic induction of VEGF in isolated endometrial stromal and epithelial cells ([@B32]), but to our knowledge, this is the first time hypoxia has been shown to be involved in VEGF induction in endometrial tissue. PGs have previously been shown to increase VEGF expression in cancer cells ([@B16], [@B33]), but we demonstrate a potential physiological role in the human endometrium.

We examined endometrial biopsies from women collected before and 3--6 months after LNG-IUS insertion for treatment of HMB. LNG-IUS insertion dramatically down-regulates endometrial progesterone receptors, providing an *in vivo* model of local endometrial progesterone deprivation ([@B27], [@B34]). In addition, progestogen exposure has been shown to reduce endometrial perfusion and profoundly decrease vasomotion ([@B35]). This may lead to endometrial hypoxia. Endometrial samples taken after LNG-IUS insertion showed a significant increase in VEGF mRNA expression. Because normal endometrial architecture is maintained in this model, our findings support the role of progesterone withdrawal and downstream hypoxia in the up-regulation of endometrial VEGF. Furthermore, the LNG-IUS is well established as a treatment for HMB, and this stimulation of VEGF production may contribute to its efficacy.

For the first time, we have demonstrated that hypoxic induction of VEGF in endometrial cells is mediated via HIF-1α. HIF-1 is a heterodimeric factor. The HIF-1α subunit undergoes proteasomal degradation in normoxia, whereas HIF-1β is constitutively expressed. In hypoxic conditions, HIF-1α binds with HIF-1β, translocates to the nucleus, and increases the transcription of target genes, including those involved in angiogenesis ([@B16], [@B17], [@B36]). HIF-1α has been shown to be induced in late secretory and menstrual endometrium ([@B19]). A hypoxic response element is present in the VEGF promoter region, and HIF-1 has been shown to regulate VEGF expression in hypoxic Hep3B cells ([@B37]). In contrast, HIF-1-independent hypoxic regulation of VEGF has been described in colon cancer cells ([@B23]). Our results suggest HIF-1 is involved in hypoxia-induced increases in endometrial VEGF production at menstruation but that PGF~2α~ acts independently of HIF to increase VEGF. A previous study of endometrial adenocarcinoma explants and cells showed that PGF~2α~ activates the ERK1/2 signaling pathway in an epidermal growth factor receptor-dependent manner to increase VEGF promoter activity ([@B33]). Additional studies are required to determine whether a similar mechanism of action is present in normal endometrial tissue.

In conclusion, our data generated from 1) in vitro cell studies, 2) ex vivo explant culture, and 3) an *in vivo* model of progesterone deprivation indicate that progesterone withdrawal, hypoxia, and PGF~2α~ are involved in production of VEGF for endometrial repair. There is evidence that women with HMB have decreased levels of VEGF during menstruation ([@B12]). These women are also known to have aberrant PG production and signaling ([@B38], [@B39]) and may therefore have suboptimal initiation of repair leading to heavy, prolonged bleeding. Additional studies are required to determine whether there is a defective hypoxic response in women with HMB, resulting in less menstrual expression of VEGF. Delineation of the physiological regulation of endometrial repair may lead to novel, efficacious treatments for these women.
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